How to Prescribe Peptides in 2026: Every Option for Providers, Compared

Medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP, FNP-BC. Last reviewed July 4, 2026.

A note on scope: This article is general information for clinicians and patients, not legal or compliance advice. Compounding and telehealth law varies by state and is changing quickly in 2026. Confirm anything practice-specific with qualified healthcare counsel and your pharmacy partner before you act.

The real decision is the supply pathway

Most providers approach peptide therapy as a clinical question, which peptide for which patient. The harder question is upstream: how does the medication legally reach the patient? The answer determines your formulary, your pricing, your compliance burden, and how much of your practice’s time the program will consume. There are six things providers actually do in 2026. Five are legitimate. One is not.

The options at a glance

1. Prescribe FDA-approved peptide drugs

The simplest route is also the narrowest. Several peptide and peptide-adjacent drugs carry full FDA approval and dispense through ordinary retail and specialty pharmacies: semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), and tesamorelin (Egrifta) among them. You prescribe them exactly as you would any other branded or generic medication, the pharmacy dispenses, and the regulatory framework is the one you already work inside every day.

The trade-off is breadth. The approved list does not include the large category of peptides patients read about (BPC-157, CJC-1295/Ipamorelin, sermorelin, GHK-Cu, and dozens more), because those are not commercially manufactured as approved finished drugs. If your patient wants one of those, the approved-drug pathway cannot supply it, and you move to the compounded route. For background on why most peptides are not FDA-approved products, see are peptides FDA-approved.

2. Partner with a 503A compounding pharmacy

This is the route that gives you the peptides patients actually ask for. A 503A pharmacy is a state-licensed compounding pharmacy that prepares a medication for one identified patient against a valid prescription. You write a patient-specific prescription, the pharmacy compounds it, and the pharmacy ships it to the patient. There is no shelf stock; every fill traces back to a named patient and a prescribing clinician.

Three things define this pathway, and each is a diligence item:

• Patient-specific prescriptions are mandatory. A 503A pharmacy cannot compound bulk inventory to sell later, and it cannot fill without a prescription for an individual patient. Your order has to identify the patient, the substance, the strength, and the directions.
• State licensure of the pharmacy matters. The pharmacy must hold licensure in its home state and a non-resident permit in the patient’s state, and your own license must cover that state. This is why a compounded program is really a state-by-state map, not a single national switch.
• The compounding rules for peptides are in motion. Section 503A limits which bulk drug substances may be compounded, and the FDA’s position on specific peptides is shifting through 2026. Whether a given peptide can be compounded today depends on your pharmacy partner’s current read. See what a 503A pharmacy is for the full framework.

The upside is real: a broad formulary, cash pricing that is usually far below branded equivalents, and a compliant, documented supply chain with sterility and endotoxin testing. The cost is the contracting and the ongoing rule-tracking, which is more than a busy practice sometimes wants to own.

3. 503B outsourcing facilities and office use

A 503B outsourcing facility is FDA-registered and can produce certain drugs in batches for office administration without a patient-specific prescription. In principle that sounds attractive for a practice that wants to keep stock on hand. In practice, as of mid-2026, the peptides most practices want are generally not available as 503B office-use stock, because 503B facilities compound from a narrow list of eligible substances and the peptide category has been under active FDA review.

For the typical outpatient practice, this route rarely applies to peptides. If you are considering office-use stock, confirm current availability and eligibility with the facility and with counsel rather than assuming a peptide is obtainable this way.

4. What is not an option: research-use-only peptides

It is worth being blunt here, because the gray market is large and the marketing is persuasive. Buying peptides sold with a “research use only” or “not for human use” label and then administering them to patients is not a legitimate supply pathway. The reasons are factual, not rhetorical:

• It is not an FDA-sanctioned drug supply. These products are not approved drugs and are not compounded under pharmacy law. The “research use only” label is a device that lets the vendor sell outside the drug framework; it does not make the material a medication.
• There is no pharmacy oversight. No 503A licensure, no USP sterility or endotoxin testing you can rely on, no pharmacist-in-charge accountable for the batch, and no verifiable chain of custody.
• The malpractice and licensure exposure is direct. Administering non-approved material outside a research setting can support disciplinary action by state medical and pharmacy boards, civil malpractice claims, and in some cases enforcement action. As of mid-2026, state boards have suspended clinic and med-spa licenses over exactly this conduct.

The disclaimer on these products protects the seller. It does nothing for the prescriber who administers the material. If a patient wants a peptide you cannot supply compliantly, the answer is a compliant pathway or a referral, never gray-market sourcing. For the patient-facing version of this distinction, see compounded peptides vs research peptides.

5. Build a telehealth peptide program in-house

If peptides are going to be a core service line, some practices build the whole stack themselves. It is a legitimate path, and it is a substantial undertaking. Honestly accounted for, it requires:

• Multi-state licensure. You (or a network of employed or contracted providers) must be licensed in every state you intend to serve. This is usually the binding constraint on how fast the program can grow.
• A 503A pharmacy relationship. A licensed compounding partner that holds the non-resident permits for your states and can compound the peptides on your formulary under current rules.
• Intake, consent, and documentation tooling. Compliant clinical intake, informed-consent capture, and record keeping that satisfies each state’s telehealth requirements.
• State telehealth compliance, not DEA. Because these peptides are non-controlled, DEA registration is not the issue. State telehealth rules (establishing the provider-patient relationship, evaluation standards, and prescribing limits) are.

The clinical medicine is the straightforward part. The licensure map, the pharmacy contracting, and the compliance operations are where the real work sits, and they do not stop once the program launches.

6. Refer to an established prescription peptide service

For most providers, the request is occasional: a patient wants a specific peptide that is outside your formulary, outside your comfort zone, or outside the states you are licensed in. Standing up a compliance program for that is disproportionate. Referring the patient to a service that already carries the licensure and the pharmacy relationship is often the cleanest answer.

RxPepsDirect is one such service, presented here as one option among several rather than a recommendation. It is a US prescription telehealth service based in Denver, Colorado, operating in 28 states through its medical director, Dr. Jonathan Snipes (NPI 1821250077). The mechanics are simple for the patient your provider points there:

• The patient pays a flat $39 one-time medical visit fee, which is the only charge RxPepsDirect collects.
• An RxPepsDirect-affiliated licensed provider reviews the patient and writes the prescription when it is clinically appropriate. The provider writes the prescription only.
• Optimal Balance Pharmacy, a licensed Texas 503A compounding pharmacy, fills, ships, and bills for the medication separately at wholesale pass-through pricing. Injectables ship pre-reconstituted, FedEx overnight, in a cooled travel case.

The formulary runs to 55-plus peptides, and prices are visible without creating an account, which makes it easy to tell a patient in advance what they will pay. RxPepsDirect handles non-controlled peptides only, and its lot testing covers sterility and endotoxin. A referring provider keeps their own relationship with the patient and simply hands off the piece they are not set up to supply. Browse the RxPepsDirect formulary and pricing. To see how these referral services compare to one another, our roundup of the best telehealth services for compounded peptides weighs them on price, pharmacy, and oversight.

How to choose between the routes

Three questions settle most cases:

1. Is the peptide an FDA-approved drug? If yes (semaglutide, tirzepatide, tesamorelin/Egrifta), prescribe it through a retail or specialty pharmacy and stop there. It is the lowest-risk path.
2. How often will you get the request? For occasional requests outside your formulary or licensed states, a referral to an established service is proportionate. For a committed service line, building the in-house program or contracting directly with a 503A pharmacy makes sense.
3. Are you prepared to track the compounding rules? The 503A route rewards depth and pricing but requires ongoing diligence on which peptides may be compounded as the FDA position evolves. If your practice cannot own that, a referral offloads it.

A word on compliance

Everything above is general information for clinicians and the patients who research on their behalf. It is not legal advice, and it is not a substitute for your own compliance review. Compounding eligibility, telehealth requirements, and pharmacy permitting vary by state and are changing quickly in 2026. Before you build a program, sign a pharmacy agreement, or write a prescription for a compounded peptide, confirm the current rules with qualified healthcare counsel and your pharmacy partner.